Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Yes. Metformin 500 mg is the standard starting dose and is considered low for weight loss. Most studies showing modest weight loss used 1,500–2,000 mg per day. Metformin is FDA-approved for type 2 diabetes, not weight loss, so weight-loss use is off-label and needs clinician review. [1,2]
What counts as a low, standard, and high dose of metformin?
Metformin hydrochloride is a biguanide medicine sold as immediate-release metformin and extended-release metformin, including brand names Glucophage, Glucophage XR, Fortamet, and Glumetza. It is FDA-approved to help control blood sugar in type 2 diabetes, not as an FDA-approved weight-loss drug. [1]
For weight-related goals, 500 mg is usually viewed as a low starting point because many clinical studies used higher total daily doses. Any possible benefit must be weighed against common side effects such as nausea, diarrhea, gas, and abdominal discomfort, plus rare but serious lactic acidosis risk in higher-risk patients. [1,2]
Immediate-release (IR) dosing
Immediate-release metformin is absorbed faster and is often started at 500 mg once or twice daily in labeled diabetes dosing. Clinicians may increase the dose gradually to improve blood sugar response while watching for stomach side effects. [1]
Extended-release (ER/XR) dosing
Extended-release metformin, also called ER or XR, releases the medicine more slowly. Some people tolerate ER/XR better, though stomach effects can still happen. ER products have different label maximums, so clinicians follow the exact product label and the patient’s kidney function. [1]
Maximum daily dose
The labeled maximum daily dose depends on the formulation. For many immediate-release products, the maximum is up to 2,550 mg per day, while some extended-release products have lower maximums such as 2,000 mg per day. Higher doses may increase side effects and are not right for everyone. [1]
| Dose range | How clinicians often describe it | Where 500 mg fits | Key cautions |
|---|---|---|---|
| 500 mg/day | Low or starting dose | Common first step | Weight change is often small; stomach side effects can still occur. [1] |
| 1,000 mg/day | Lower-standard daily dose | Above the usual starting dose | Tolerance and kidney function still matter. [1] |
| 1,500–2,000 mg/day | Common study and clinical range | Higher than 500 mg | Many weight-loss studies used this range; GI effects may increase. [2,3] |
| Above 2,000 mg/day | High dose for some formulations | Well above 500 mg | Product-specific maximums apply; lactic acidosis risk must be considered. [1] |
Why do most people start at 500 mg?
Most people start low because 500 mg can help the body adjust before a clinician considers higher doses. Metformin’s most common side effects are digestive: diarrhea, nausea, gas, indigestion, and abdominal discomfort. Starting low and increasing slowly is a common way to improve tolerance. [1]
This does not mean 500 mg is risk-free. Metformin has a boxed warning for lactic acidosis, a rare but serious condition that is more likely in people with significant kidney impairment, certain acute illnesses, heavy alcohol use, or other risk factors listed in the label. [1]
Reducing GI side effects
GI side effects are one reason clinicians may prefer a slow approach. In the Diabetes Prevention Program, gastrointestinal symptoms were more common with metformin than placebo, even though the medication was effective for diabetes prevention in higher-risk adults. [2]
The standard titration schedule
A typical label-based pattern is to begin with a low dose, then raise the total daily dose in steps if tolerated and clinically needed. The timing and amount of each change depend on the formulation, symptoms, blood sugar goals, kidney function, and the clinician’s plan. [1]
What dose of metformin is used for weight loss in studies?
Metformin for weight loss is off-label. It has been studied most often in people with type 2 diabetes, prediabetes, insulin resistance, or polycystic ovary syndrome, also called PCOS. Benefits are usually modest, and the same studies and labels note digestive side effects and safety limits. [1,2,3,4]
Diabetes Prevention Program: 1,700 mg/day
In the Diabetes Prevention Program, adults at high risk for type 2 diabetes were assigned lifestyle change, placebo, or metformin 850 mg twice daily. The metformin group had lower diabetes incidence than placebo and lost about 2.1 kg on average over 2.8 years, but GI symptoms were more common. [2]
Meta-analysis findings: doses over 1,500 mg/day
A meta-analysis in people with obesity found that metformin was linked with a small reduction in body mass index, with larger effects in some groups and at doses above 1,500 mg per day. These findings do not remove the need to screen for kidney risk and side effects. [3]
Where 500 mg fits in
At 500 mg per day, metformin is usually a starting dose, not the dose used in many weight-loss studies. Some people may notice appetite or weight changes, but the average effect at this dose is usually expected to be limited, and side effects can still occur. [1,2,3]
How much weight can you lose on 500 mg vs. higher doses?
There is no guaranteed amount of weight loss with 500 mg metformin. In longer studies using higher doses, average weight loss was modest. In the Diabetes Prevention Program Outcomes Study, people originally assigned to metformin had more long-term weight loss than placebo, but results varied and GI effects remained an important trade-off. [4]
For some people, metformin may help reduce appetite or improve insulin resistance, which can support weight control. For others, the scale may not change much. Individual results vary, and metformin should not be used as a stand-alone weight-loss promise. [2,3,4]
| Metformin dose pattern | What studies suggest | What to keep in mind |
|---|---|---|
| 500 mg/day | Usually considered a starting dose; weight change is often minimal. | Side effects can still happen, and weight-loss use is off-label. [1] |
| About 1,500–2,000 mg/day | Many studies showing modest weight change used this range. | Higher doses may not be tolerated and require kidney safety review. [1,2,3] |
| Long-term use in DPP follow-up | Metformin was linked with modest long-term weight differences in some participants. | Benefits varied; it is not an FDA-approved obesity medication. [4] |
How and when is the dose increased?
Clinicians often consider increasing metformin after the body has had time to adjust, commonly in stepwise changes over weeks. The goal may be blood sugar control, insulin resistance, prediabetes risk reduction, or an off-label weight-related goal. Dose changes should only be made by a licensed clinician. [1,2]
A clinician may pause or lower a planned increase if side effects are hard to manage, if kidney function is reduced, or if another medication changes the risk profile. This is why a “higher dose” is not automatically better. [1]
Who might stay on a lower dose?
Some people stay on 500 mg or another lower dose because it is the best balance of tolerability and benefit for them. This is common when stomach side effects, kidney function, age, or other medical issues make higher doses less appropriate. [1]
Kidney function, or eGFR, considerations
Kidney function is measured with eGFR, or estimated glomerular filtration rate. The FDA label says metformin is contraindicated when eGFR is below 30 mL/min/1.73 m², and starting it is not recommended when eGFR is between 30 and 45 mL/min/1.73 m². [1]
Side-effect tolerance
Digestive side effects are a common reason to stay at a lower dose or use an extended-release product. A clinician may also review alcohol intake, dehydration risk, liver disease, heart failure, upcoming imaging with contrast, and other factors tied to lactic acidosis risk. [1]
How does metformin compare to GLP-1 medications for weight loss?
GLP-1 receptor agonists are different from metformin. Semaglutide is the generic name in Ozempic and Wegovy; Wegovy is FDA-approved for chronic weight management in certain adults and adolescents, while Ozempic is FDA-approved for type 2 diabetes and other labeled cardiometabolic uses, not weight loss. [5,6]
Tirzepatide is the generic name in Mounjaro and Zepbound; Zepbound is FDA-approved for chronic weight management in certain adults, while Mounjaro is FDA-approved for type 2 diabetes. Compounded semaglutide and compounded tirzepatide may be dispensed by licensed 503A pharmacies when legally appropriate, but compounded versions are not FDA-approved drugs. [7,8,9]
In major trials, semaglutide and tirzepatide led to larger average weight loss than metformin studies, but they also have side effects and contraindications. Common GLP-1 and GIP/GLP-1 side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain; labels also include warnings such as pancreatitis risk and thyroid C-cell tumor warnings for certain patients. [5,7,10,11]
| Option | FDA status for weight loss | Main mechanism | Typical weight-loss evidence | Common cautions | Access notes |
|---|---|---|---|---|---|
| Metformin | Not FDA-approved for weight loss; approved for type 2 diabetes. [1] | Lowers liver glucose production and improves insulin sensitivity. | Modest average weight loss in studies, often at higher daily doses than 500 mg. [2,3,4] | GI side effects; boxed warning for rare lactic acidosis; kidney function limits. [1] | Often low-cost generic prescription. |
| Semaglutide, including Wegovy/Ozempic and compounded semaglutide | Wegovy is FDA-approved for chronic weight management in eligible patients; Ozempic is not approved for weight loss. Compounded semaglutide is not FDA-approved. [5,6,9] | GLP-1 receptor agonist that affects appetite, fullness, and glucose regulation. | STEP 1 showed about 14.9% mean weight loss with semaglutide 2.4 mg plus lifestyle change at 68 weeks. [10] | GI side effects; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2. [5] | Brand prescriptions or, when legally appropriate, compounded options through licensed pharmacies. |
| Tirzepatide, including Zepbound/Mounjaro and compounded tirzepatide | Zepbound is FDA-approved for chronic weight management in eligible adults; Mounjaro is approved for type 2 diabetes. Compounded tirzepatide is not FDA-approved. [7,8,9] | GIP and GLP-1 receptor agonist that affects appetite, fullness, and glucose regulation. | SURMOUNT-1 showed large average weight reductions at 72 weeks in adults with obesity or overweight and related conditions. [11] | GI side effects; boxed warning for thyroid C-cell tumors; not for certain thyroid cancer risk histories. [7] | Brand prescriptions or, when legally appropriate, compounded options through licensed pharmacies. |
How to get metformin or a GLP-1 through a licensed telehealth provider
A licensed clinician can review your health history, current medications, lab needs, kidney function, and weight-related goals before deciding whether metformin, a GLP-1 medication, or another plan is appropriate. This matters because metformin is off-label for weight loss, and GLP-1 options have specific FDA indications, contraindications, and side effects. [1,5,7]
Chia is one licensed telehealth option that can evaluate eligibility for prescription weight-loss care, including compounded GLP-1 options when appropriate. A 503A compounding pharmacy prepares patient-specific prescriptions under state pharmacy oversight and federal compounding rules; compounded drugs are not FDA-approved and should be used only with clinician oversight. [9]
3-min quiz
Explore prescription options with a clinician
If you are comparing metformin and GLP-1 options, a clinician can help review eligibility, safety factors, and lab needs before any prescription decision.
Frequently asked questions
For many people, 500 mg is a starting dose and weight loss is usually minimal. Studies that found modest weight loss often used higher daily doses, such as 1,500–2,000 mg per day, but higher doses also raise tolerability and safety questions. [1,2,3]
No. Metformin is FDA-approved for blood sugar control in type 2 diabetes. Using metformin for weight loss, prediabetes, insulin resistance, or PCOS-related weight concerns is off-label and should be reviewed by a clinician. [1]
Weight changes, when they happen, are usually gradual. In the Diabetes Prevention Program, average weight loss was measured over years, not days. Side effects can appear earlier, especially digestive symptoms. [2,4]
Metformin is sometimes used with GLP-1 medicines in type 2 diabetes care, but whether that is appropriate depends on the person, the indication, kidney function, side effects, and other medications. Combination decisions should be made by a licensed clinician. [5,7,12]
The most common issues are digestive side effects. The most serious labeled risk is rare lactic acidosis, which is why kidney function and other risk factors must be assessed. [1]
Yes. AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP at mcp.chia.health. A licensed clinician still decides whether any medication is appropriate.
3-min quiz
Talk with a licensed clinician
A clinician can help you understand whether metformin, a GLP-1 medication, or a non-medication plan fits your health history and goals.
References
- 1.U.S. Food and Drug Administration. Metformin hydrochloride tablets prescribing information, 2023.
- 2.Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 2002.
- 3.Pu R, Shi D, Gan T, et al. Effects of metformin in obesity treatment in different populations: a meta-analysis. Therapeutic Advances in Endocrinology and Metabolism, 2020.
- 4.Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care, 2012.
- 5.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information, 2024.
- 6.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information, 2024.
- 7.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information, 2024.
- 8.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information, 2024.
- 9.U.S. Food and Drug Administration. Compounding and the FDA: Questions and answers, 2024.
- 10.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 11.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- 12.American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2024. Diabetes Care, 2024.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
